Caveolin involvement and modulation in breast cancer

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 13, 2011, Pages 1143-1152

  Aoki, M N ^a   Amarante, M K ^b   Oda, J M M ^b   Watanabe, M A E ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Breast cancer; Caveolae; Caveolin 1

Indexed keywords

ACETYLSALICYLIC ACID; BRCA1 PROTEIN; BRCA2 PROTEIN; CAVEOLIN 1; FILAMIN A; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7;

ARTICLE; BREAST CANCER; CARCINOGENESIS; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; MODULATION; NONHUMAN;

ANIMALS; BREAST; BREAST NEOPLASMS; CAVEOLAE; CAVEOLIN 1; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; SIGNAL TRANSDUCTION;

EID: 80054057428     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711797655344     Document Type: Article

References (94)

1. Yamada, E. The fine structure of the gall bladder epithelium of the mouse. J. Bioph. and Bioch. Cytol., 1955, 1(5), 445-458.
2. Palade, G. E. Fine structure of blood capillaries. J. Appl. Physiol., 1953, 24, 14-24.
3. Rothberg, K.G.; Heuser, J.E.; Donzell, W.C.; Ying, Y. S.; Glenney, J. R.; Anderson, R.G. Caveolin, a protein component of caveolae membrane coats. Cell, 1992, 68(4), 673-82.
4. Parton, R.G. and Simons, K. The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol., 2007, 8, 185-194.
5. Liu, P.; Rudick, M.; and Anderson, R.G. Multiple functions of caveolin-1. J. Biol. Chem., 2002, 277(41), 295-241; 298.
6. Razani, B.; Woodman, S.E.; and Lisanti, M.P. Caveolae: from cell biology to animal physiology. Pharmacol. Rev., 2002, 54: 431-467.
7. Burgermeister, E.; Liscovitch, M.; Rocken, C.; Schmid, R.; Ebert, M. Caveats of caveolin-1 in cancer progression. Cancer Lett., 2008, 268(2), 187-201.
8. Sonnino, S.; Prinetti, A. Sphingolipids and membrane environments for caveolin. FEBS Lett., 2009, 583(4), 597-606.
9. Cohen, A.W.; Hnasko, R.; Schubert, W.; Role of caveolae and caveolins in health and disease. Physiol. Rev., 2004, 84, 1341-379.
10. Anderson, R.G. The caveolae membrane system. Annu. Rev. Biochem., 1998, 67, 199-225.
11. Okamoto, T.; Schlegel, A.; Scherer, P.E.; Lisanti, M.P. Caveolins, a family of scaffolding proteins for organizing preassembled signaling complexes at the plasma membrane.; J. Biol. Chem., 1998, 273(10), 5419-22.
12. Chang, S.H.; Feng, D.; Nagy, J.A.; Sciuto, T.E.; Dvorak, A.M.; Dvorak, H.F. Vascular Permeability and Pathological Angiogenesis in Caveolin-1-Null Mice. Am. J. Pathol., 2009, 175(4), 1768-76.
13. Rivera, M.; Muto, A.; Feigel, A.; Kondo, Y.; Dardik, A. Venous and arterial identity: a role for caveolae? Vascular, 2009, 17, Suppl 1:S10-S14.
14. Balijepalli, R.C.; Kamp, T.J. Caveolae, ion channels and cardiac arrhythmias. Prog. Biophys. Mol. Biol., 2008, 98(2-3):149-160.
15. Medina, F.A.; Cohen, A.W.; de Almeida, C.J.; Nagajyothi, F.; Braunstein, V.L.; Teixeira, M.M.; Tanowitz, H.B.; Lisanti, M.P. Immune dysfunction in caveolin-1 null mice following infection with Trypanosoma cruzi (Tulahuen strain). Microbes Infect., 2007, 9(3), 325-33.
16. Luoma, J.I.; Boulware, M.I.; Mermelstein, P.G. Caveolin proteins and estrogen signaling in the brain. Mol. Cell Endocrinol., 2008, 290, 8-13.
17. Trigatti, B.L.; Anderson, R.G.; Gerber, G.E. Identification of caveolin-1 as a fatty acid binding protein. Biochem. Biophys. Res. Commun., 1999, 255(1), 34-9.
18. Vogel, V.; Sheetz, M. Local force and geometry sensing regulate cell functions. Nature Rev. Mol. Cell Biol., 2006, 7, 265-275.
19. Deregowski, V.; Delhalle, S.; Benoit, V.; Bours, V.; Merville, M.P. Identification of cytokine-induced nuclear factor-kappaB target genes in ovarian and breast cancer cells. Biochem. Pharmacol., 2002, 64(5-6), 873-881.
20. Wanaski, S.P.; Ng, B.K.; Glaser, M. Caveolin scaffolding region and the membrane binding region of SRC form lateral membrane domains. Biochemistry, 2003, 42(1):42-56.
21. Goetz, J.G.; Lajoie, P.; Wiseman, S.M.; Nabi, I.R. Caveolin-1 in tumor progression: the good, the bad and the ugly; Cancer Metastasis Rev., 2008, 27, 715-735.
22. Quest, A.F.; Gutierrez-Pajares, J.L.; Torres, V.A. Caveolin-1: an ambiguous partner in cell signalling and cancer. J. Cell Mol. Med., 2008, 12(4), 1130-1150.
23. Williams, T.M.; Cheung, M.W.; Park, D.S.; Razani, B.; Cohen, A.W.; Muller, W.J.; Di Vizio, D.; Chopra, N.G.; Pestell, R.G.; Lisanti, M.P. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol. Biol. Cell., 2003, 14(3),1027-1042.
24. Williams, T.M.; Sotgia, F.; Lee, H.; Hassan, G.; Di Vizio, D.; Bonuccelli, G.; Capozza, F.; Mercier, I.; Rui, H.; Pestell, R.G.; Lisanti, M.P. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am. J. Pathol., 2006, 169(5), 1784-1801.
25. Razani, B.; Engelman, J.A.; Wang, X.B. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities, J. Biol. Chem., 2001, 276, 38121-38138.
26. Lee, H.; Volonte, D.; Galbiati, F.; Iyengar, P.; Lublin, D.M.; Bregman, D.B.; Wilson, M.T.; Campos-Gonzalez, R.; Bouzahzah, B.; Pestell, R.G.; Scherer, P.E.; Lisanti, M.P. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol. Endocrinol., 2000, 14(11), 1750-1775.
27. Glenney, J.R. Tyrosine phosphorylation of a 22 kD protein is correlated with transformation with Rous sarcoma virus. J. Biol. Chem., 1989, 264, 20163-20166.
28. Corley-Mastick, C., Brady, M. J., and Saltiel, A.R. J. Role of caveolin and caveolae in insulin signaling and diabetes. Cell Biol., 1995, 129, 1523-1531.
29. Glenney, J.R., Zokas, L. Novel tyrosine kinase substrates from Rous sarcoma virus transformed cells are present in the membrane cytoskeleton. J. Cell Biol., 1989, 108, (6):2401-408.
30. Nomura, R., Fujimoto, T. Tyrosine-phosphorylated caveolin-1: immune localization and molecular characterization. Mol. Biol. Cell., 1999, 10(4), 975-986.
31. Goetz, J.G.; Lajoie, P.; Wiseman, S.M.; Nabi, I.R. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev., 2008, 27(4), 715-735.
32. Couet, J.; Li, S.; Okamoto, T.; Ikezu, T.; Lisanti, M. P. Identification of peptide and protein ligands for the caveolin scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem., 1997, 272(10), 6525-6533.
33. Garcia-Cardena, G.; Martasek, P.; Masters, B. S.; Skidd, P. M.; Couet, J.; Li, S. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J. Biol. Chem., 1997, 272(41), 25437-440.
34. Li, S.; Couet, J.; Lisanti, M. P. Src tyrosine kinases, G alpha subunits, and H-Ras share a common membrane anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J. Biol. Chem., 1996, 271(46), 29182-190.
35. Li, S.; Okamoto, T.; Chun, M.; Sargiacomo, M.; Casanova, J. E.; Hansen, S. H. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J. Bio.l Chem., 1995, 270(26), 15693-15701.
36. Ostrom, R. S.; Insel, P. A. The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology. Br. J. Pharm., 2004, 143(2), 235-245.
37. Engelman, J.A.; Zhang, X.L.; Lisanti, M.P. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett., 1998, 436(3), 403-410.
38. Engelman, J. A.; Wykoff, C. C.; Yasuhara, S.; Song, K. S.; Okamoto, T.; Lisanti, M. P. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorageindependent growth. J. Biol. Chem., 1997, 272(26), 16374-16381.
39. Lim, K.H.; Ancrile, B.B.; Kashatus, D.F.; Counter, C.M. Tumour maintenance is mediated by eNOS. Nature, 2008, 452(7187), 646-649.
40. Shyamala, G.; Chou, Y.C.; Cardiff, R.D.; Vargis, E. Effect of cneu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. Cancer Res., 2006, 66(21):10391-10398.
41. Vasei, M.; Modjtahedi, H.; Ale-Booyeh, O.; Mosallaei, A.; Kajbafzadeh, A.M.; Shahriari, M.; Ghaderi, A.A.; Soleymanpour, H.; Kosari, F.; Moch, H.; Sauter, G. Amplification and expression of EGFR and ERBB2 in Wilms tumor. Cancer Genet. Cytogenet., 2009, 194(2), 88-95.
42. Fiucci, G.; Ravid, D.; Reich, R.; Liscovitch, M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene, 2002, 21(15):2365-2375.
43. Hurlstone, A.F.; Reid, G.; Reeves, J.R.; Fraser, J.; Strathdee, G.; Rahilly, M.; Parkinson, E.K.; Black, D.M. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene, 1999, 18(10),1881-1890.
44. Shajahan, A.N.; Wang, A.; Decker, M.; Minshall, R.D.; Liu, M.C.; Clarke, R. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J Biol Chem. 2007, 282(8), 5934-5943.
45. Zhu, H.; Weisleder, N.; Wu, P.; Cai, C.; Chen, J.W. Caveolae/caveolin-1 are important modulators of store-operated calcium entry in Hs578/T breast cancer cells. J. Pharmacol Sci. 2008, 106(2), 287-294.
46. Hino, M.; Doihara, H.; Kobayashi, K.; Aoe, M.; Shimizu, N. Caveolin-1 as tumor suppressor gene in breast cancer. Surg. Today, 2003, 33(7), 486-490.
47. Ravid, D.; Maor, S.; Werner, H.; Liscovitch, M. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene, 2005, 24(8), 1338-1347.
48. Razandi, M.; Oh, P.; Pedram, A.; Schnitzer, J. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol. Endocrinol., 2002, 16(1), 100-115.
49. Zhang, X.; Shen, P.; Coleman, M.; Zou, W.; Loggie, B.W.; Smith, L.M.; Wang, Z. Caveolin-1 down-regulation activates estrogen receptor alpha expression and leads to beta-estradiol-stimulated mammary tumorigenesis. Anticancer Res., 2005, 25(1A), 369-375.
50. Sotgia, F.; Williams, T.M.; Schubert, W.; Medina, F.; Minetti, C.; Pestell, R.G.; Lisanti, M.P. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am. J. Pathol., 2006, 168(1), 292-309.
51. Cai, C.; Chen, J. Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int. J. Cancer, 2004, 111(4), 522-529.
52. Zhu, H.; Cai, C.; Chen, J. Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1. FEBS Lett., 2004, 576(3), 369-374.
53. Storch, C.H.; Ehehalt, R.; Haefeli, W.E.; Weiss, J.; Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J. Pharmacol. Exp. Ther. 2007, 323(1), 257-64.
54. Dasari, A.; Bartholomew, J.N.; Volonte, D.; Galbiati, F. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1- mediated activation of two GC-rich promoter elements. Cancer Res., 2006, 66(22), 10805-10814.
55. Hayashi, K.; Matsuda, S.; Machida, K.; Yamamoto, T.; Fukuda, Y.; Nimura, Y.; Hayakawa, T.; Hamaguchi, M. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res., 2001, 61(6), 2361-2364.
56. Li, T.; Sotgia, F.; Vuolo, M.A.; Li, M.; Yang, W.C.; Pestell, R.G.; Sparano, J.A.; Lisanti, M.P. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am. J. Pathol., 2006, 168(6), 1998-2013.
57. Lee, H.; Park, D.S.; Razani, B.; Russell, R.G.; Pestell, R.G.; Lisanti, M.P. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am. J. Pathol., 2002, 161(4), 1357-1369.
58. Pinilla, S.M.; Honrado, E.; Hardisson, D.; Benítez, J.; Palacios, J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res. Treat., 2006, 99(1), 85-90.
59. Glait, C.; Tencer, L.; Ravid, D.; Sarfstein, R.; Liscovitch, M.; Werner, H. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Exp. Cell Res., 2006, 312(19), 3899-3908.
60. Wang, Y.; Yu, J.; Zhan, Q. BRCA1 regulates caveolin-1 expression and inhibits cell invasiveness. Biochem. Biophys. Res. Commun., 2008, 370(2), 201-206.
61. Salatino, M.; Beguelin, W.; Peters, M.G.; Carnevale, R.; Proietti, C.J.; Galigniana, M.D.; Vedoy, C.G.; Schillaci, R.; Charreau, E.H.; Sogayar, M.C.; Elizalde, P.V. Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation. Oncogene. 2006, 25(59), 7723-7739.
62. Elsheikh, S.E.; Green, A.R.; Rakha, E.A.; Samaka, R.M.; Ammar, A.A.; Powe, D.; Reis-Filho, J.S.; Ellis, I.O. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triplenegative immunophenotype. Br. J. Cancer. 2008, 99(2), 327-334.
63. Zou, W.; McDaneld, L.; Smith, L.M. Caveolin-1 haploinsufficiency leads to partial transformation of human breast epithelial cells. Anticancer Res., 2003, 3(6C), 4581-4586.
64. Liedtke, C.; Kersting, C.; Bürger, H.; Kiesel, L.; Wülfing, P. Caveolin-1 expression in benign and malignant lesions of the breast. World J. Surg. Oncol., 2007, 5, 110.
65. Wu, P.; Wang, X.; Li, F.; Qi, B.; Zhu, H.; Liu, S.; Cui, Y.; Chen, J. Growth suppression of MCF-7 cancer cell-derived xenografts in nude mice by caveolin-1. Biochem. Biophys. Res. Commun., 2008, 376(1), 215-220.
66. Glait, C.; Tencer, L.; Ravid, D.; Sarfstein, R.; Liscovitch, M.; Werner, H.; Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Exp. Cell Res., 2006, 312(19):3899-908.
67. Engelman, J.A.; Zhang, X.L.; Lisanti, M.P. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5' promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett., 1999, 448(2-3), 221-230.
68. Sloan, E.K.; Stanley, K.L.; Anderson, R.L. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene. 2004, 23(47), 7893-7897.
69. Chen, S.T.; Lin, S.Y.; Yeh, K.T.; Kuo, S.J.; Chan, W.L.; Chu, Y.P.; Chang, J.G. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers. Int. J. Mol. Med., 2004, 14(4), 577-582.
70. Sloan, E.K.; Ciocca, D.R.; Pouliot, N.; Natoli, A.; Restall, C.; Henderson, M.A.; Fanelli, M.A.; Cuello-Carrión, F.D.; Gago, F.E.; Anderson, R.L. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am. J. Pathol., 2009, 174(6), 2035-2043.
71. Sotgia, F.; Rui, H.; Bonuccelli, G.; Mercier, I.; Pestell, R.G.; Lisanti, M.P. Caveolin-1, mammary stem cells, and estrogendependent breast cancers. Cancer Res., 2006, 66(22), 10647-10651.
72. Witkiewicz, A.K.; Dasgupta, A.; Nguyen, K.H.; Liu, C.; Kovatich, A.J.; Schwartz, G.F.; Pestell, R.G.; Sotgia, F.; Rui, H.; Lisanti, M.P. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer; Cancer Biol. Ther., 2009, 8(11), 1071-1079.
73. Mercier, I.; Casimiro, M.C.; Wang, C.; Rosenberg, A.L.; Quong, J.; Minkeu, A.; Allen, K.G.; Danilo, C.; Sotgia, F.; Bonuccelli, G.; Jasmin, J.F.; Xu, H.; Bosco, E.; Aronow, B.; Witkiewicz, A.; Pestell, R.G.; Knudsen, E.S.; Lisanti, M.P. Human breast cancerassociated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy; Cancer Biol. Ther., 2008, 7(8), 1212-1225.
74. Perrone, G.; Altomare, V.; Zagami, M.; Morini, S.; Petitti, T.; Battista, C.; Muda, A.O.; Rabitti, C. Caveolin-1 expression in human breast lobular cancer progression. Mod. Pathol., 2009, 22(1), 71-78.
75. Savage, K.; Lambros, M.B.K.; Robertson, D.; Jones, R.L.; Jones C.; Mackay, A.; James, M.; Hornick, J.L.; Pereira, E.M.; Milanezi, F.; Fletcher, C.D.M.; Schmitt, F.C.; Ashworth, A.; Reis-Filho, J.S. Caveolin1 is Overexpressed and Amplified in a Subset of Basallike And Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis. Clin. Cancer Res., 2007, 13(1), 90-101.
76. Van den Eynden, G.G.; Van Laere, S.J.; Van der Auwera, I.; Merajver, S.D.; Van Marck, E.A.; van Dam, P.; Vermeulen, P.B.; Dirix, L.Y.; van Golen, K.L. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res. Treat., 2006, 95(3), 219-228.
77. Bau D.T.; Tsai, M.H.; Tsou, Y.A.; Wang, C.H.; Tsai, C.W.; Sun, S.S.; Hua, C.H.; Shyue, S.K.; Tsai, R.Y. The association of caveolin-1 genotypes with oral cancer susceptibility in taiwan. Ann. Surg. Oncol., 2011, 18(5):1431-1438.
78. Mei-Due, Y.; Ru-Yin, T.; Chiu-Shong L.; Chao-Hsiang C.; Hwei-Chung W.; Yung-An T.; Chung-Hsing W.; Cheng-Chieh L.; Song-Kun S.; Da-Tian B. Association of Caveolin-1 polymorphisms with colorectal cancer susceptibility in Taiwan. World J. Gastrointest. Oncol., 2010, 2(8), 326-331.
79. Sagara, Y.; Mimori, K.; Yoshinaga, K.; Tanaka, F.; Nishida, K.; Ohno, S.; Inoue, H.; Mori, M. Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br. J. Cancer, 2004, 91(5), 959-965.
80. Huot P.S; Sarkar, B.; Ma, D.W. Conjugated linoleic acid alters caveolae phospholipid fatty acid composition and decreases caveolin-1 expression in MCF-7 breast cancer cells. Nutr. Res., 2010, 30(3), 179-185.
81. Buitrago, C.; Boland, R. Caveolae and caveolin-1 are implicated in 1alpha,25(OH)(2)-vitamin D(3)-dependent modulation of Src, MAPK cascades and VDR localization in skeletal muscle cells. J. Steroid Biochem. Mol. Biol., 2010, 121(1-2), 169-175.
82. Liu, L.B.; Xue, Y.X.; Liu, Y.H. Bradykinin increases the permeability of the blood-tumor barrier by the caveolae-mediated transcellular pathway. J. Neurooncol., 2010, 99(2), 187-194.
83. Hurlstone, A.F.; Reid, G.; Reeves, J.R.; Fraser, J.; Strathdee, G.; Rahilly, M.; Parkinson, E.K.; Black, D.M.; Analysis of the Caveolin-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene, 1999, 18(10), 1881-1890.
84. Yi, T.N.; Zhao, H.Y.; Zhang, J.S.; Shan, H.Y.; Meng, X.; Zhang, J. Effect of aspirin on high glucose-induced senescence of endothelial cells. Chin. Med. J., 2009, 122(24), 3055-3061.
85. Zhang, S.; Liu, Y.; Zhao, Z.; Xue, Y. Effects of green tea polyphenols on caveolin-1 of microvessel fragments in rats with cerebral ischemia. Neurol. Res., 2010, 32(9), 963-970.
86. Song, J.H.; Kim, M.; Park, S.W.; Chen, S.W.; Pitson, S.M.; Lee, H.T. Isoflurane via TGF-beta1 release increases caveolae formation and organizes sphingosine kinase signaling in renal proximal tubules. Am. J. Physiol. Renal Physiol., 2010, 298(4), F1041-1050.
87. Suh, J.W.; Choi, D.J.; Chang, H.J.; Cho, Y.S.; Youn, T.J.; Chae, I.H.; Kim, K.I.; Kim, C.H.; Kim, H.S.; Oh, B.H.; Park, Y.B. HMGCoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase. J. Korean Med. Sci., 2010, 25(1), 16-23.
88. Parat, M.O. Could endothelial caveolae be the target of general anaesthetics? Br. J. Anaesth., 2006, 96(5), 547-550.
89. Ravid, D.; Chuderland, D.; Landsman, L.; Lavie, Y.; Reich, R.; Liscovitch, M. Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration. Exp. Cell Res., 2008, 314(15), 2762-2773.
90. Petrelli, F.; Cabiddu, M.; Ghilardi, M.; Barni, S. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based? Expert Opin. Investig. Drugs., 2009 18(10), 1467-1477.
91. Howell A.; Landberg G.; Bergh, J. Breast tumour stroma is a prognostic indicator and target for therapy. Breast Cancer Res., 2009, 11(Suppl 3), S16.
92. Martinez-Outschoorn U.E.; Whitaker-Menezes D.; Lin Z.; Flomenberg N.; Howell A.; Pestell R.G.; Sotgia F.; Lisanti M.P.; Sotgia F. Cytokine production and inflammation drive autophagy in the tumor microenvironment: Role of stromal caveolin-1 as a key regulator. Cell Cycle, 2011 1,10(11).
93. Bouras T.; Lisanti M.P.; Pestell R.G. Caveolin-1 in breast cancer. Cancer Biol. Ther., 2004, 3(10),931-941.
94. Carver L.A.; Schnitzer J.E. Caveolae: mining little caves for new cancer targets. Nat. Rev. Cancer., 2003, 3(8),571-581.